BIOCRYST PHARMACEUTICALS INC (BCRX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
BCRX currently has 242M outstanding shares. with minimal authorized share overhang for future dilution. The company has diluted shareholders by 17.17% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 06, 2026 |
10-Q filing | 242.3M shares outstanding |
240M | 0 |
| Nov 04, 2025 |
10-Q filing | 210.2M shares outstanding |
210M | 0 |
| Aug 05, 2025 |
10-Q filing | 209.5M shares outstanding |
210M | 0 |
| May 06, 2025 |
10-Q filing | 208.9M shares outstanding |
210M | 0 |
| Feb 25, 2025 |
10-K filing | 206.7M shares outstanding |
210M | 0 |
| Nov 05, 2024 |
10-Q filing | 206.9M shares outstanding |
210M | 0 |
| Aug 06, 2024 |
10-Q filing | 206.4M shares outstanding |
210M | 0 |
| May 07, 2024 |
10-Q filing | 206.1M shares outstanding |
210M | 0 |
| Feb 27, 2024 |
10-K filing | 192.2M shares outstanding |
190M | 0 |
| Nov 08, 2023 |
10-Q filing | 189.6M shares outstanding |
190M | 0 |
| Aug 07, 2023 |
10-Q filing | 189.1M shares outstanding |
190M | 0 |
| May 08, 2023 |
10-Q filing | 188.5M shares outstanding |
190M | 0 |
| Feb 27, 2023 |
10-K filing | 185.9M shares outstanding |
190M | 0 |
| Nov 04, 2022 |
10-Q filing | 186.2M shares outstanding |
190M | 0 |
| Aug 05, 2022 |
10-Q filing | 185.6M shares outstanding |
190M | 0 |
| May 09, 2022 |
10-Q filing | 184.9M shares outstanding |
180M | 0 |
| Feb 28, 2022 |
10-K filing | 179.1M shares outstanding |
180M | 0 |
| Nov 22, 2021 |
8-K filing: BioCryst Pharmaceuticals, Inc. entered into a Common Stock Purchase Agreement with RPI 2019 Intermediate Finance Trust to issue 3,846,154 shares of common stock at $13.00 per share for $50 million. ($50.0M proceeds) |
180M | 0 |
| Nov 04, 2021 |
10-Q filing | 179.8M shares outstanding |
180M | 0 |
| Aug 09, 2021 |
10-Q filing | 178.7M shares outstanding |
180M | 0 |
| May 07, 2021 |
10-Q filing | 177.3M shares outstanding |
180M | 0 |
| Mar 01, 2021 |
10-K filing | 167.3M shares outstanding |
170M | 0 |
| Nov 06, 2020 |
10-Q filing | 176.5M shares outstanding |
180M | 0 |
| Aug 07, 2020 |
10-Q filing | 161.6M shares outstanding |
160M | 0 |
| Jun 01, 2020 |
8-K filing: BioCryst Pharmaceuticals, Inc. completed an underwritten public offering of common stock and pre-funded warrants, including the exercise of the underwriters' option, resulting in gross proceeds of $115 million. |
150M | 36K |
| May 11, 2020 |
10-Q filing | 154.2M shares outstanding |
150M | 36K |
| Apr 24, 2020 |
S-3 filing: BioCryst Pharmaceuticals, Inc. may offer up to $500,000,000 in various securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, as described in the prospectus and any accompanying supplements. |
150M | 0 |
| Mar 13, 2020 |
10-K filing | 154.2M shares outstanding |
150M | 0 |